Navid Malik, an analyst at Matrix, said he imagined that the provisions put in place by GSK this year deal with the bulk of the litigation risks going forward.
"While there has likely been an increase in legal advertising related to gathering plaintiffs in the US for Avandia – this typically happens in the US –
I am wondering whether the negative news since 2007 has already flushed out many of the plaintiffs," he said."It is possible that lawyers may gather more interest from new plaintiffs but I don't think the floodgates are about to open."
via telegraph.co.uk
In 2009, there were more than 33,000 airings of Avandia-related adverts in America, valued at $6.5m (£4.1m). But last year, that rose to 52,000 airings at a value of $14.8m.
No comments:
Post a Comment